REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update and Program Updates for RGX-314 for the Treatment of Wet AMD
Go back to REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update and Program Updates for RGX-314 for the Treatment of Wet AMD| Jennison Natural Resources Fund Class B (NASDAQ: RGNX) | Delayed: 9.95 +0.88 (9.70%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.07 | 52 Week High | $25.00 | |||
| Open | $8.94 | 52 Week Low | $7.07 | |||
| Day High | $10.34 | P/E | N/A | |||
| Day Low | $8.94 | EPS | $0.00 | |||
| Volume | 2,968,183 | |||||
